Literature DB >> 24133825

First-line treatment for patients with CML in chronic phase: why imatinib is an appropriate choice.

Charles A Schiffer1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24133825

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  1 in total

1.  The evolution of dasatinib dosage over the years and its relevance to other anticancer medications.

Authors:  Charles A Schiffer
Journal:  Cancer       Date:  2018-05-03       Impact factor: 6.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.